Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.93 USD | +2.76% | -2.11% | -34.04% |
May. 13 | Transcript : Lucid Diagnostics Inc., Q1 2024 Earnings Call, May 13, 2024 | |
May. 13 | Lucid Diagnostics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- Low profitability weakens the company.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the past year, analysts have significantly revised downwards their profit estimates.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-34.04% | 46.33M | - | ||
+73.10% | 12.38B | B- | ||
-19.92% | 7.81B | C+ | ||
+8.05% | 6.72B | C- | ||
+12.49% | 5.39B | D+ | ||
+40.80% | 5.03B | - | ||
-17.97% | 4.72B | B | ||
-22.01% | 4.06B | B- | ||
-28.94% | 2.68B | C | ||
+61.09% | 2.59B | C- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- LUCD Stock
- Ratings Lucid Diagnostics Inc.